What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the impact of erythropoietin on tissue oxygenation in patients with sickle cell disease.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 1b/2 trial shows erythropoietin boosts cerebral oxygenation but not muscle in sickle cell disease, indicating distinct tissue responses.

To evaluate the impact of erythropoietin on tissue oxygenation in patients with sickle cell disease.
Phase 1b/2 trial involving patients with sickle cell disease
Participants received erythropoietin treatment for 12 weeks
Tissue oxygen saturation measured using near-infrared spectroscopy at multiple time points
Paired t-tests and linear mixed-effects models were utilized for analysis.
Mean hemoglobin levels increased significantly from 7.6 to 10.6 g/dL after treatment (p<0.001).
Cerebral StO₂ improved from 49.4% to 55.1% at 12 weeks (p=0.017), while muscle StO₂ remained unchanged.
At 24 weeks, mean Hb levels decreased to 8.5 g/dL, with no significant changes in StO₂ observed.

Tukakira et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1b/2 trial shows erythropoietin boosts cerebral oxygenation but not muscle in sickle cell disease, indicating distinct tissue responses.